References
- Banfalvi T, Gilde K, Boldizsar M, Kremmer T. Clinical significance of 5-S-cysteinyldopa monitor-ing in patients with malignant melanoma. Neoplasma 2002; 49: 121–5.
- Kamen R, Kagedal B, Lindholm C, Nilsson B, Arstrand K, Ringborg U. The value of cysteinyl-dopa in the follow-up of disseminated malignant melanoma. Melanoma Res 2000; 10: 363–9.
- Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 1997; 57: 5073–6.
- Banfalvi T, Gilde K, Boldizsar M, Fejos Z, Horvath B, Liszkay G, Beczassy E, Kremmer T. Serum concentration of 5-S-cysteinyldopa in patients with melanoma. Eur J Clin Invest 2000; 30: 900–4.
- Horikoshi T, Ito S. Serum 5-5-cysteinyldopa (5-S-CD) as a marker of melanoma progression. J Dermatol 1992; 19: 809–13.
- Kamen R, von Schoultz E, Hansson LO, Nilsson B, Arstrand K, Kagedal B. S 1 00B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res 1997; 7: 393–9.
- Sasaki Y, Shimizu H, Naka W, Takeshita E, Nishikawa T. Evaluation of the clinical usefulness of measuring urinary excretion of 5-5-cysteinyl-dopa in melanoma: ten years' experience of 50 patients. Acta Derm Venereol 1997; 77: 379–81.
- Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H. Evaluation of melanin-related metabo-lites as markers of melanoma progression. Cancer 1994; 73: 629–36.
- Wakamatsu K, Kageshita T, Furue M, Hatta N, Kiyohara Y, Nakayama J, Ono T, Saida T, Takata M, Tsuchida T, Uhara H, Yamamoto A, Yamazaki N, Naito A, Ito S. Evaluation of 5-5-cysteinyldopa as a marker of melanoma progression: 10 years' experience. Melanoma Res 2002; 12: 245–53.
- Banfalvi T, Gilde K, Gergye M, Boldizsar M, Kremmer T, Otto S. Use of serum 5-S-CD and 5-100B protein levels to monitor the clinical course of malignant melanoma. Eur J Cancer 2003; 39: 164 — 9.
- Banfalvi T, Boldizsar M, Gergye M, Gilde K, Kremmer T, Otto S. Comparison of prognostic significance of serum 5-5-cysteinyldopa, LDH and 5-100B protein in Stage III-IV malignant mela-noma. Pathol Oncol Res 2002; 8: 183–7.
- Kagedal B, Källberg M, Arstrand K, Hansson C. Automated high-performance liquid chroma-tographic determination of 5-S-cysteiny1-3,4-dihydroxyphenylalanine in urine. J Chromatogr 1989; 473: 359–70.
- KAgedal B, Pettersson A. Determination of 5-S-L-cysteinyl-L-dopa in serum by high-performance liquid chromatography after prepurification with immobilized boric acid. In: Bagnara J, Klaus SN, Paul E, Schartl M, editors. Pigment Cell 1985. Biological, molecular and clinical aspects of pigmentation. Tokyo: University of Tokyo Press; 1985. p. 721–7.
- Blanchard J. Evaluation of the relative efficacy of various techniques for deproteinizing plasma sam-ples prior to high-performance liquid chromato-graphic analysis. J Chromatogr 1981; 226: 455–60.
- Kagedal B, Pettersson A. Liquid-chromatographic determination of 5-S-L-cysteinyl-L-dopa with elec-trochemical detection in urine prepurified with a phenylboronate affinity gel. Clin Chem 1983; 29: 2031 — 4.
- Agrup G, Edholm LE, Rorsman H, Rosengren E. Diastereomers of 5-5-cysteinyldopa. Acta Derm Venereol 1983; 63: 59–61.
- Hartleb J, Damm Y, Arndt R, Christophers E, Stockfleth E. Determination of 5-5-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction—high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma. J Chromatogr B Biomed Sci Appl 1999; 727: 31–42.
- Wakamatsu K, Ito S. Improved HPLC determina-tion of 5-5-cysteinyldopa in serum. Clin Chem 1994; 40: 495–6.